Verastem (VSTM) Reports Clinical Data from the Pivotal Phase 3 DUO
Tweet Send to a Friend
Verastem, Inc. (NASDAQ: VSTM) today announced the presentation of the results from the Phase 3 DUO study evaluating the efficacy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
